CORC

在结果中检索

CORC

浏览/检索结果: 共48条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial 期刊论文
CLINICAL CANCER RESEARCH, 2019, 卷号: 25, 期号: 17, 页码: 5212-5220
作者:  Li, Qiao;  Guan, Xiuwen;  Chen, Shanshan;  Yi, Zongbi;  Lan, Bo
收藏  |  浏览/下载：15/0  |  提交时间：2020/07/01
Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study 期刊论文
2019, 卷号: 8, 期号: 13, 页码: 5823-5830
作者:  Yang Guangjian;  Ma Di;  Xu Haiyan;  Yang Lu;  Li Junling
收藏  |  浏览/下载：3/0  |  提交时间：2020/01/03
Co-mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer 期刊论文
2019
作者:  Xing Puyuan;  Han Xiaohong;  Wang Sha;  Liu Yutao;  Yang Sheng
收藏  |  浏览/下载：21/0  |  提交时间：2020/01/03
Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study 期刊论文
2019, 卷号: 31, 期号: 3, 页码: 481-+
作者:  Xing, Puyuan;  Ma, Di;  Wang, Qiang;  Hao, Xuezhi;  Wang, Mengzhao
收藏  |  浏览/下载：15/0  |  提交时间：2020/01/03
Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I-III Lung Adenocarcinoma 期刊论文
2019, 卷号: 9, 页码: 556
作者:  Han, Xiaohong;  Tan, Qiaoyun;  Yang, Sheng;  Li, Junling;  Xu, Jianping
收藏  |  浏览/下载：19/0  |  提交时间：2020/01/03
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial 期刊论文
2019, 卷号: 25, 期号: 17, 页码: 5212-5220
作者:  Li Qiao;  Guan Xiuwen;  Chen Shanshan;  Yi Zongbi
收藏  |  浏览/下载：6/0  |  提交时间：2020/01/03
Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in China 期刊论文
2019, 卷号: 9, 期号: 5, 页码: e028589
作者:  Jiang, Shiyu;  Liu, Peng;  Yang, Sheng;  Yang, Jianliang;  Wu, Dawei
收藏  |  浏览/下载：10/0  |  提交时间：2020/01/03
Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment 期刊论文
2019, 卷号: 31, 期号: 2, 页码: 349-356
作者:  Xu, Haiyan;  Ma, Di;  Yang, Guangjian;  Li, Junling;  Hao, Xuezhi
收藏  |  浏览/下载：10/0  |  提交时间：2020/01/03
Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib 期刊论文
2019, 卷号: 14, 期号: 3, 页码: 335-342
作者:  Mu, Yuxin;  Hao, Xuezhi;  Yang, Ke;  Ma, Di;  Wang, Shouzheng
收藏  |  浏览/下载：5/0  |  提交时间：2020/01/03
Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib 期刊论文
2019, 卷号: 10, 期号: 5, 页码: 1213-1219
作者:  Ma, Di;  Zhang, Yan;  Xing, Puyuan;  Hao, Xuezhi;  Wang, Mengzhao
收藏  |  浏览/下载：5/0  |  提交时间：2020/01/03

©版权所有 ©2017 CSpace - Powered by CSpace